Detalhe da pesquisa
1.
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
Breast Cancer Res
; 17: 18, 2015 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25849327
2.
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
BMC Cancer
; 15: 978, 2015 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26674097
3.
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
JAMA
; 302(13): 1429-36, 2009 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-19809024
4.
Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
Eur J Hum Genet
; 11(6): 464-7, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12774040
5.
Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series.
In Vivo
; 28(2): 235-41, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24632979
6.
Radiotherapy of internal mammary lymph nodes in breast cancer. Principle considerations on the basis of dosimetric data.
Strahlenther Onkol
; 178(1): 18-24, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11977387
7.
Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.
Hered Cancer Clin Pract
; 2(3): 139-45, 2004 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20233468